Completion of Clinical Trial for PRX-002 Developed by Prothena Corporation


(March 20, 2015) - A recently completed clinical trial for a new drug PRX-002, being developed by Prothena Corporation, has demonstrated a key ability to reduce the presence of alpha-synuclein, an enzyme thought to be associated with Parkinson's disease. Read more…

Click for a printer friendly version

Back to top